Nanobiotix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.07.19	Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology (GlobeNewswire)
01.07.19	Nanobiotix announces new organizational structure as the company enters its next stage after first european market approval (GlobeNewswire)
04.06.19	NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL (GlobeNewswire)
28.05.19	Nanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare (GlobeNewswire)
09.04.19	Nanobiotix Raises Approximately EUR 29.5 Million in Placement of Ordinary New Shares (Businesswire)
08.04.19	NANOBIOTIX Launches a Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
04.04.19	Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval (GlobeNewswire)
02.04.19	Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer (GlobeNewswire)
26.03.19	Nanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback (GlobeNewswire)
15.03.19	Nanobiotix 2018 Annual Results (GlobeNewswire)
04.03.19	Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank (GlobeNewswire)
16.01.19	Nanobiotix Plans to Conduct Registered Public Offering in the United States (GlobeNewswire)
07.01.19	Nanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3 (GlobeNewswire)
19.10.18	NANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO (GlobeNewswire)
16.10.18	Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank (GlobeNewswire)
26.09.18	Nanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual c (GlobeNewswire)
20.09.18	Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 (GlobeNewswire)
04.09.18	NANOBIOTIX half year results for the six months ended June 30, 2018 (GlobeNewswire)
26.07.18	NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank (GlobeNewswire)
21.06.18	NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 (GlobeNewswire)
06.06.18	NANOBIOTIX' Management statement on recent share price variation (GlobeNewswire)
03.05.18	Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers (GlobeNewswire)
17.04.18	AACR annual meeting 2018: Nanobiotix presented preclinical data showing NBTXR3 nanoparticles can activate the cGAS-STING pathway (GlobeNewswire)
10.04.18	NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB (GlobeNewswire)
30.03.18	NANOBIOTIX : Nanobiotix 2017 Annual Results (GlobeNewswire)
28.02.18	Nanobiotix 2017 Q4 and Annual Revenues (Businesswire)
22.01.18	Nanobiotix Presents First Promising Data from Phase I/II Liver Cancers Trial of NBTXR3 at the American Society of Clinical Oncology Gastrointestinal Annual Meeting (Businesswire)
22.01.18	NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting (GlobeNewswire)
11.01.18	NANOBIOTIX Partners with the Providence Cancer Institute to Run Immunotherapeutic Preclinical Research in Pancreatic Cancers (Businesswire)
11.01.18	NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers (GlobeNewswire)
26.12.17	Nanobiotix: 2017 Review and 2018 Expected Milestones (Businesswire)
26.12.17	NANOBIOTIX : 2017 review and 2018 expected milestones (GlobeNewswire)
26.12.17	NANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial (GlobeNewswire)
15.11.17	Nanobiotix revenues for the 3rd quarter of 2017 (Businesswire)
13.11.17	Nanobiotix Presented New Clinical and Pre-Clinical Data Confirming NBTXR3’s Significant Potential Role In Immuno-Oncology at SITC Annual Meeting (Businesswire)
13.11.17	NANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting (GlobeNewswire)
09.11.17	Nanobiotix Provides Update on the Global Development of Its Lead Product NBTXR3 (Businesswire)
09.11.17	NANOBIOTIX provides update on the global development of its lead product NBTXR3 (GlobeNewswire)
31.10.17	NANOBIOTIX Successfully Completes Approximately Eur 27.2 Million Placement of New Shares (Businesswire)
30.10.17	Nanobiotix Launches Capital Increase by Means of an Accelerated Bookbuild Offering (Businesswire)
23.10.17	NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma (GlobeNewswire)
28.09.17	Nanobiotix Plans to Conduct Its First Clinical Trial with NBTXR3 in Combination with Immune Checkpoint Inhibitors in the U.S. (Businesswire)
28.09.17	NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. (GlobeNewswire)
31.08.17	Nanobiotix half year results for the six months ended 30 June 2017 (Businesswire)
31.08.17	NANOBIOTIX half year results for the six months ended 30 June 2017 (GlobeNewswire)
12.07.17	Nanobiotix Revenues for the 2nd Quarter of 2017 (Businesswire)
15.05.17	Nanobiotix revenue for the 1st quarter of 2017 (Businesswire)
28.04.17	Nanobiotix: 2016 Annual Results (Businesswire)
28.11.16	NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3 (GlobeNewswire)
15.11.16	Nanobiotix Revenue for Q3 2016 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	75.32	0.61 %	K V
Givaudan	4’083.00	0.54 %	K V
Kuehne+Nagel Int	203.40	0.39 %	K V
Lonza Grp	542.40	0.18 %	K V
Swiss Life Hldg	692.00	0.00 %	K V
Sika	224.70	-0.66 %	K V
Swisscom	503.50	-0.69 %	K V
Swiss Re	130.85	-0.83 %	K V
UBS Group	27.93	-0.85 %	K V
Nestle	74.50	-0.96 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nanobiotix SA

Aktien Top/Flop

Meistgelesene Nachrichten